FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020397948> ?p ?o ?g. }

• W2020397948 endingPage "441" @default.
• W2020397948 startingPage "435" @default.
• W2020397948 abstract "Seminars in DialysisVolume 7, Issue 6 p. 435-441 Optimal Management of Renal Osteodystrophy in Children Treated with CAPD and CCPD Jorge A. Ramirez, Jorge A. Ramirez Departments of Pediatrics, Medicine and Radiological Sciences, University of California. Los Angeles, School of Medicine, Los Angeles, California and Arnold Palmer Hospital for Children and Women, Orlando, FloridaSearch for more papers by this authorWilliam G. Goodman, William G. Goodman Departments of Pediatrics, Medicine and Radiological Sciences, University of California. Los Angeles, School of Medicine, Los Angeles, California and Arnold Palmer Hospital for Children and Women, Orlando, FloridaSearch for more papers by this authorIsidro B. Salusky, Corresponding Author Isidro B. Salusky Departments of Pediatrics, Medicine and Radiological Sciences, University of California. Los Angeles, School of Medicine, Los Angeles, California and Arnold Palmer Hospital for Children and Women, Orlando, FloridaUCLA Medical Center, Division of Pediatric Nephrology, MDCC A2–383, Los Angeles. CA 90024Search for more papers by this author Jorge A. Ramirez, Jorge A. Ramirez Departments of Pediatrics, Medicine and Radiological Sciences, University of California. Los Angeles, School of Medicine, Los Angeles, California and Arnold Palmer Hospital for Children and Women, Orlando, FloridaSearch for more papers by this authorWilliam G. Goodman, William G. Goodman Departments of Pediatrics, Medicine and Radiological Sciences, University of California. Los Angeles, School of Medicine, Los Angeles, California and Arnold Palmer Hospital for Children and Women, Orlando, FloridaSearch for more papers by this authorIsidro B. Salusky, Corresponding Author Isidro B. Salusky Departments of Pediatrics, Medicine and Radiological Sciences, University of California. Los Angeles, School of Medicine, Los Angeles, California and Arnold Palmer Hospital for Children and Women, Orlando, FloridaUCLA Medical Center, Division of Pediatric Nephrology, MDCC A2–383, Los Angeles. CA 90024Search for more papers by this author First published: November 1994 https://doi.org/10.1111/j.1525-139X.1994.tb00808.xCitations: 2AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Lucas RC: On a form of late rickets associated with albuminuria. rickets of adolescence. Lancet 1993, 1883. 2 Alexander SR, Sullivan EK, Harmon WH, Stablein DM, Tejani A.: Maintenance dialysis in North American children and adolescents: A preliminary report. Kidney Int 44(Suppl 43): S104–S109, 1992. 3 Goodman WG, Coburn JW, Ramirez JA, Slatopolsky E., Salusky IB: Renal osteodvstroohy in adult and wdiatric patients, in Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism, edited by M. Favus New York , Raven Press, 1993, p. 304. 4 Portale AA, Boothe BE, Tsai HC, Morris RC Jr.: Reduced plasma concentration of 1.25-dihydroxy-vitamin D in children with moderate renal insufficiency. Kidney Int 21: 627–632, 1982. 5 Wilson L., Felsenfeld A., Drezner MK, Liach F.: Altered divalent ion metabolism in early renal failure: Role of 1,25(OH)2D. Kidney Int 27: 565–573, 1985. 6 Reichel H., Deibart B., SchmidtGayk H., Ritz E.: Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 6: 162–169, 1991. 7 Silver J., Naveh-Many T., Mayer H., Schmelzer HJ, Popovtzer MM: Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78: 1296–1301, 1986. 8 Szabo A., Merke J., Beier E., et al.: 1,25(OH)2 vitamin D, Inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 35: 1049–1056, 1989. 9 Korkor AB: Reduced binding of 3H-1,25-dihydroxyvitamin D in the parathyroid glands of patients with renal failure. N Engl J Med 316: 1573–1577, 1987. 10 Fukagawa M., Kitaoka M., Kaname S., Okazaki R., Matsumoto T., Ogata E., Hoshino M., Inada T., Sekine T., Kurokawa K.: Suppression of parathyroid gland hyperplasia by 1,25(OH)2D3 pulse therapy. N Engl J Med 315: 421–422, 1990. 11 Brown EM: Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56: 572–581, 1983. 12 McCarron DA, Muther RS, Lenfesty B., Bennet WM: Parathyroid function in persistent hyperparathyroidism: Relationship to gland size. Kidney Int 22: 662–670, 1982. 13 David DS, Sakai S., Brennan L., Riggio RA, Cheigh J., Stenzel K., Rubin AL, Sherwood LM: Hypercalcemia after renal transplantation: Long-term follow-up data. N Engl J Med 289: 398–401, 1973. 14 Felsenfeld AJ, Rodriguez M., Dunlay R., Llach F.: A comparison of parathyroid-gland function in hemodialysis patients with different forms of renal osteodystrophy. Nephrol Dial Transplant 6: 244–251, 1991. 15 Delmez JA, Tindira C., Grooms P., Dusson A., Windus DW, Slatopolsky E.: Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 83: 1349–1355, 1989. 16 Dunlay R., Rodriguez M., Felsenfeld AJ, Llach F.: Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 36: 1093–1098, 1989. 17 Ramirez JA, Goodman WG, Gornbein J., Menezes C., Moulton L., Segre GV, Salusky IB: Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 76: 1489–1494, 1993. 18 Fukuda N., Tanaka H., Tominaga Y., Fukagawa M., Kurokawa K., Seino Y.: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92: 1436–1443, 1993. 19 Shusterman NH, Wasserstein AG, Morrison G., Audet P., Fallon MD, Kaplan F.: Controlled study of renal osteodystrophy in patients undergoing dialysis. Improved response to continuous ambulatory peritoncal dialysis compared with hemodialysis. Am J Med 82: 1148–1156, 1987. 20 Salusky IB, Fine RN, Kangarloo H., Gold R., Paunier L., Goodman WG, Brill JE, Gilli G. Slatopolsky E., Coburn JW: “High-dose” calcitriol for control of renal osteodystrophy in children on CAPD. Kidney Int 32: 89–95, 1987. 21 Paunier L., Salusky IB, Slatopolsky E., Kangarloo H., Kopple JD, Horst RL, Coburn JW, Fine RN: Renal osteodystrophy in children undergoing continuous ambulatory peritoneal dialysis. Pediatr Res 18: 742–747, 1984. 22 Buccianti G., Bianchi ML, Valenti G.: Progress of renal osteodystrcphy during continuous ambulatory peritoneal dialysis. Clin Nephrol 22: 279–283, 1984. 23 Gokal R., Ramos JM, Ellis HA, Parkinson I., Sweetman V., Dewar J., Ward MK, Kerr DNS: Histological renal osteodystrophy and 25-hydroxy-cholccalciferol and aluminum levels in patients on continuous ambulatory peritoneal dialysis. Kidney Int 23: 15–21, 1983. 24 Delmez JA, Slatopolsky E., Martin KJ, Gearing BN, Harter HR: Minerals, vitamin D. and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int 21: 862–867, 1982. 25 Rottenbourg J., Gallego JL, Jaudon M., Clavel J., Legrain M.: Serum concentration and peritoneal transfer of aluminum during treatment by continuous ambulatory peritoneal dialysis. Kidney Int 25: 919–924, 1984. 26 Parker A., Nolph KD: Magnesium and calcium mass transfer during continuous ambulatory peritoneal dialysis. ASAO Trans 26: 194–196, 1980. 27 Rapoport J., Shaney S., Chaimoviu C.: Continuous ambulatory peritoneal dialysis and vitamin D. Nephron 48: 1–3, 1988. 28 Goldstein DA, Haldimann B., Sherman D., Norman AW, Massry SG: Vitamin D metabolites and calcium metabolism in patients with nephtotic syndrome and normal renal function. J Clin Endocrinol Metab 52: 116–120, 1981. 29 Shenard DJ, Coburn JW, Brickman AS, Singer FR, Maloney N.: Skeletal response to treatment with 1,25 dihydroxyvitamin D in renal failure. Contrib Nephrol 18: 92, 1980. 30 Cassidy MJ, Owen JP, Ellis HA, Dewar J. Robinson CJ, Wilkinson R., Ward MK, Kerr DN: Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis. Q J Med 54: 29–48, 1985. 31 Mathias RS, Salusky IB, Harmon WH, Paredes A., Emans J., Segre GV, Goodman WG: Renal bone disease in pediatric patients and young adults treated by hemodialysis in a children's hospital. J Am Soc Nephrol 12: 1938–1946, 1993. 32 Salusky IB, Ramirez JA, Oppenheim WL, Gales B., Segre GV, Goodman WG: Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int. in press. 33 Sherrard DJ, Hercz G., Pei Y., Maloney N., Greenwood C., Manuel A., Saiphoo C., Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure—An evolving disorder. Kidney lnt 43: 436–442.1993. 34 Salusky IB, Coburn JW, Brill J., Foley J., Slatopolsky E., Fine RN, Goodman WG: Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33: 975–982, 1988. 35 Quarks LD, Lobaugh B., Murphy G.: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75: 145–150.1992. 36 Cohen-Solal ME, Sebert JL, Boudailliez B., Marie A., Moriniere P., Gueris J., Bouillon R., Fournier A.: Comparison of intact, midregion. and carboxy-terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 73: 516–524, 1991. 37 Slatopolsky E., Bricker NS: The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 4: 141–145, 1973. 38 Salusky IB, Coburn JW, Paunier L., Sherrard DJ, Fine RN: Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis. J Pediatr 105: 717–720, 1984. 39 Salusky IB, Coburn JW, Foley J., Nelson P., Fine RN: Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminumsontaining gels in children receiving dialysis. J Pediatr 108: 767–770.1986. 40 Blumenkrantz MJ, Kopple JD, Moral JK, Coburn JW: Nitrogen and urea metabolism during continuous ambulatory peritoneal dialysis. Kidney Int 20: 78–82, 1981. 41 Kaehny WD, Hegg P., Alfrey AC: Gastrointestinal absorption of aluminum from aluminum-containing antacids. N Engl J Med 296: 1389–1390, 1977. 42 Salusky IB, Foley J., Nelson P., Goodman WG: Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324: 527–531, 1991. 43 Froment DP, Molitoris BA, Buddington B., Miller N., Alfrey AC: Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate. Kidney Int 36: 978–984, 1989. 44 Moriniere PH, Roussel A., Tahiri Y., Fornire A.: Substitution of aluminum hydroxide by high doses of calcium carbonate in patients on chronic hemodialysis: Disappearance of hyperaluminemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc 19: 784–787, 1982. 45 Slatopolsky E., Weens C., Lopez-Hilker S., Nomood K., Zink M., Windus M., Delmet J.: Calcium carbonate is an effective phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315: 157–161.1986. 46 Mai ML, Emmett M., Sheikh MS, Santa Ana CA, Schiller L., Fordtran JS: Calcium acetate, an dective phosphorus binder in patients with renal failure. Kidney Int 36: 690–695, 1989. 47 Schaefer K., Scheer J., Asmus G., Umlaut E., Hagemann J., von Herrath D.: The treatment uraemic hyperphosphataemia with calcium acetate and calcium carbonate: A comparative study. Nephrol Dial Transplant 6: 171–175, 1991. 48 Sykes B., Puddle B., Francis M., Smith R.: The estimation of two collagens from human dermis by interrupted gel electrophoresis. Biochem Biophys Res Commun 72: 1472–1480, 1976. 49 Foumier A., Moriniere PH, Sebert JL, Dkhissi H., Atik A., Leflon P., Renaud H., Gueris J., Gregoire I., Idrissi A., Garabedian M.: Calcium carbonate. an aluminum-h agent for control of hyperphosphatemia. hypocalcemia and hyperparathyroidism in uremia. Kidney Int 29 (Suppl 18): S115–S119, 1986. 50 Renaud H., Atik A., Herve M., Moriniere P., Hocine C., Belbrik S., Fournier A.: Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: Lack of influence of calcium carbonate. Nephron 48: 28–32, 1988. 51 Hercz G., Pei Y., Greenwood C., Manuel A., Saiphoo C., Goodman WG, Segre GV, Fenton S., Sherrard DJ: Aplastic osteodystrophy without aluminum: The role of “suppressed” parathyroid function. Kidney Int 44: 860–866, 1993. 52 O'Donovan R., Baldwin D., Hammer M., et al.: Substitution of aluminum salts by magnesium salts in control of dialysis hyperphosphatemia. Lancet 1: 880–882, 1986. 53 Mactier RA, Leung ACT, Henderson IS, et al.: Control of hyperphosphatemia in dialysis patients: Comparison of aluminum hydroxide, calcium carbonate and magnesium trisilicate. Dial Transplant Nephrol 11: 599–610, 1987. 54 Breuer J. Moniz C., Baldwin D., Persons V.: The effects of zero magnesium dialysate and magnesium supplements on ionized calcium concentration in patients on regular dialysis treatment. Nephrol Dial Transplant 2: 347–350, 1987. 55 Slatopolsky E., Weerts C., Norwood K., Giles K., Fryer P., Finch J., Windus D., Delmez J.: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism, Kidney Int 36: 897–903, 1989. 56 Goodman WG, Salusky IB: Evolution Of secondary hyperparathy-roidism during daily oral calcitriol therapy in pediatric renal osteod-ystrophy. Contrib Nephrol 90: 189–195, 1991. 57 Slatopolsky E., Weerts C., Thielan J., Horst RL, Harter H., Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74: 2136–2143, 1984. 58 Andress DL, Norris KC. Coburn JW, Slatopolsky EA. Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274–279, 1989. 59 Delmez JA, Hugan CS, Gearing BK, Rothstein M., Windus DW, Rapp N., Slatopolsky E.: The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 31: 795–799, 1987. 60 Salusky IB, Goodman WG, Horst R., Segre GV, Kim L., Norris KC, Adam IS, Holloway M., Fine RN, Coburn JW: Pharmakokinetics of calcitriol in CAPDlCCPD patients. Am J Kidney Dis 16: 126–132, 1990. 61 Klaus G., Mehls O., Hinderer J., Ritz E.: Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism. Lancet 337: 800–801, 1991. 62 Reichel H., Szabo A., Uhl J., Pesian S., Schmutz A., Schmidt-Gayk H., Ritz E.: Intermittent versus continuous administration of 1,25-dihydroxyvitarnin D, in experimental renal hyperparathyroidism. Kidney Int 44: 1259–1265, 1993. 63 Brown AJ, Ritter CR, Finch JL, Momssey J., Martin KJ, Murayama E., Nishii Y., Slatopolsky E.: The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84: 728–732, 1989. Citing Literature Volume7, Issue6November 1994Pages 435-441 ReferencesRelatedInformation" @default.
• W2020397948 created "2016-06-24" @default.
• W2020397948 creator A5072032639 @default.
• W2020397948 creator A5081105301 @default.
• W2020397948 creator A5084811951 @default.
• W2020397948 date "2007-10-01" @default.
• W2020397948 modified "2023-09-26" @default.
• W2020397948 title "Optimal Management of Renal Osteodystrophy in Children Treated with CAPD and CCPD" @default.
• W2020397948 cites W1510697686 @default.
• W2020397948 cites W1900206056 @default.
• W2020397948 cites W1964057973 @default.
• W2020397948 cites W1969851962 @default.
• W2020397948 cites W1970131674 @default.
• W2020397948 cites W1978987630 @default.
• W2020397948 cites W1984488246 @default.
• W2020397948 cites W1989640819 @default.
• W2020397948 cites W1994403324 @default.
• W2020397948 cites W1999393117 @default.
• W2020397948 cites W1999778136 @default.
• W2020397948 cites W2001480762 @default.
• W2020397948 cites W2007811985 @default.
• W2020397948 cites W2020010772 @default.
• W2020397948 cites W2029871508 @default.
• W2020397948 cites W2031888876 @default.
• W2020397948 cites W2034468185 @default.
• W2020397948 cites W2036259344 @default.
• W2020397948 cites W2039377258 @default.
• W2020397948 cites W2044523494 @default.
• W2020397948 cites W2046397527 @default.
• W2020397948 cites W2047494468 @default.
• W2020397948 cites W2055923382 @default.
• W2020397948 cites W2057121857 @default.
• W2020397948 cites W2062181374 @default.
• W2020397948 cites W2067484667 @default.
• W2020397948 cites W2070530147 @default.
• W2020397948 cites W2072647000 @default.
• W2020397948 cites W2078817914 @default.
• W2020397948 cites W2079984725 @default.
• W2020397948 cites W2085312682 @default.
• W2020397948 cites W2087809285 @default.
• W2020397948 cites W2088115301 @default.
• W2020397948 cites W2090127918 @default.
• W2020397948 cites W2093988218 @default.
• W2020397948 cites W2113219485 @default.
• W2020397948 cites W2113376778 @default.
• W2020397948 cites W2130054095 @default.
• W2020397948 cites W2148217123 @default.
• W2020397948 cites W2152597878 @default.
• W2020397948 cites W2152928463 @default.
• W2020397948 cites W2156887647 @default.
• W2020397948 cites W2242741430 @default.
• W2020397948 cites W2268089337 @default.
• W2020397948 cites W2320589260 @default.
• W2020397948 cites W2330058697 @default.
• W2020397948 cites W2330513287 @default.
• W2020397948 cites W2336662282 @default.
• W2020397948 cites W3028210632 @default.
• W2020397948 doi "https://doi.org/10.1111/j.1525-139x.1994.tb00808.x" @default.
• W2020397948 hasPublicationYear "2007" @default.
• W2020397948 type Work @default.
• W2020397948 sameAs 2020397948 @default.
• W2020397948 citedByCount "3" @default.
• W2020397948 crossrefType "journal-article" @default.
• W2020397948 hasAuthorship W2020397948A5072032639 @default.
• W2020397948 hasAuthorship W2020397948A5081105301 @default.
• W2020397948 hasAuthorship W2020397948A5084811951 @default.
• W2020397948 hasConcept C126322002 @default.
• W2020397948 hasConcept C126894567 @default.
• W2020397948 hasConcept C177713679 @default.
• W2020397948 hasConcept C2776699218 @default.
• W2020397948 hasConcept C2778653478 @default.
• W2020397948 hasConcept C2779056158 @default.
• W2020397948 hasConcept C2781000923 @default.
• W2020397948 hasConcept C71924100 @default.
• W2020397948 hasConceptScore W2020397948C126322002 @default.
• W2020397948 hasConceptScore W2020397948C126894567 @default.
• W2020397948 hasConceptScore W2020397948C177713679 @default.
• W2020397948 hasConceptScore W2020397948C2776699218 @default.
• W2020397948 hasConceptScore W2020397948C2778653478 @default.
• W2020397948 hasConceptScore W2020397948C2779056158 @default.
• W2020397948 hasConceptScore W2020397948C2781000923 @default.
• W2020397948 hasConceptScore W2020397948C71924100 @default.
• W2020397948 hasIssue "6" @default.
• W2020397948 hasLocation W20203979481 @default.
• W2020397948 hasOpenAccess W2020397948 @default.
• W2020397948 hasPrimaryLocation W20203979481 @default.
• W2020397948 hasRelatedWork W1482176385 @default.
• W2020397948 hasRelatedWork W2010143507 @default.
• W2020397948 hasRelatedWork W2070528642 @default.
• W2020397948 hasRelatedWork W2153207426 @default.
• W2020397948 hasRelatedWork W2164150167 @default.
• W2020397948 hasRelatedWork W2181832966 @default.
• W2020397948 hasRelatedWork W2431362066 @default.
• W2020397948 hasRelatedWork W2521286201 @default.
• W2020397948 hasRelatedWork W2952578122 @default.
• W2020397948 hasRelatedWork W4285820443 @default.
• W2020397948 hasVolume "7" @default.
• W2020397948 isParatext "false" @default.

• next